Car T Cell Therapy

Since 2017, the FDA has approved six Car T cell therapies for treating blood cancers like Lymphomas, certain types of Leukemia and most recently, multiple myeloma. Patients eligible for Car T cell therapy must meet FDA criteria and be in overall good health to handle the waiting period and potential side effects. Their T cell health must also be sufficient for successful treatment. Seeking guidance from an oncologist is crucial to determining eligibility.